Abstract
Orlistat, an antiobesity drug with well-documented efficacy in weight reduction and maintenance, has beneficial effects on metabolic variables. It reduces the incidence of Type 2 diabetes in patients with impaired glucose tolerance and decreases LDL-C levels to a greater degree than expected from weight loss alone. Orlistat is a useful therapy in overweight and obese subjects with cardiovascular risk factors. The combination of orlistat with statins, fenofibrate and ezetimibe led to greater reductions of LDL-C levels compared with each monotherapy. The combination of orlistat with fenofibrate or ezetimibe also further decreased the concentration of atherogenic, small, dense LDL-C, as well as total plasma lipoprotein-associated phospholipase A2 activity, and improved several cardiovascular risk factors compared with monotherapy. However, studies investigating the combination of orlistat with other hypolipidemic drugs only included a small number of subjects with hyperlipidemia or the metabolic syndrome.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
